Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Clinical trial NCT05761951 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05761951
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-29
- Primary completion
- 2027-01-31
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.